Kane Biotech Inc. (CVE:KNE – Get Free Report)’s share price reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as C$0.02 and last traded at C$0.03, with a volume of 421000 shares changing hands. The stock had previously closed at C$0.03.
Kane Biotech Stock Performance
The firm’s 50-day moving average is C$0.03 and its 200 day moving average is C$0.03. The company has a current ratio of 0.45, a quick ratio of 0.39 and a debt-to-equity ratio of -135.17. The firm has a market capitalization of C$6.15 million, a price-to-earnings ratio of -3.00 and a beta of 1.06.
About Kane Biotech
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.
Recommended Stories
- Five stocks we like better than Kane Biotech
- SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
- The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity
- Palantir’s CEO Just Called Out OpenAI and Anthropic
- Abivax: Wall Street Catches Up to the Data
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
